2月25日，长春高新盘中上涨2.04%，截至14:22，报90.22元/股，成交3.69亿元，换手率1.03%，总市值 368.04亿元。 资料显示，长春高新技术产业(集团)股份有限公司位于吉林省长春市高新海容广场B座27层(震宇街与东 蔚山路交汇),香港铜锣湾希慎道33号利园1期19楼1915室，成立日期1993年6月10日，上市日期1996年12 月18日，公司主营业务涉及生物制药及中成药的研发、生产和销售,辅以房地产开发、物业管理和服务 等业务。主营业务收入构成为：制药业92.83%，房地产6.81%，服务业0.36%。 长春高新所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：疫苗、肝炎治疗、 生物疫苗、东北振兴、阿尔茨海默等。 截至9月30日，长春高新股东户数10.41万，较上期减少4.63%；人均流通股3840股，较上期增加4.85%。 2025年1月-9月，长春高新实现营业收入98.07亿元，同比减少5.60%；归母净利润11.65亿元，同比减少 58.23%。 资金流向方面，主力资金净流入4389.73万元，特大单买入4206.91万元，占比11.42%，卖出1314.96万 ...

（责任编辑：董萍萍 ） A股三大指数今日涨跌不一，截至收盘，沪指涨0.27%，深成指涨0.09%，创业板指跌0.57%，北证 50指数跌0.16%，沪深京三市成交额29923亿元，较上日放量708亿元，三市超3600只个股飘绿。 板块题 材上，有色金属、石油天然气、煤炭、化学化工、大豆、半导体、房地产板块涨幅居前；光伏设备、生 物疫苗、教育、军工装备、美容护理、PEEK材料概念股跌幅居前。 ETF方面，大宗商品板块掀涨停潮，金价站上5300美元，平安基金黄金股票ETF基金、国泰基金黄 金股票ETF和永赢基金黄金股ETF涨停。华泰柏瑞基金中韩半导体ETF涨7.43%。原油股走强，银华基金 油气资源ETF涨5.44%。 疫苗股领跌，疫苗ETF跌2.87%。光伏板块走低，光伏ETF易方达跌2%。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

Domestic Market Overview - The domestic market experienced a pullback after an initial rise, with the Shanghai Composite Index closing at 4132.61 points, down 0.09%, and the Shenzhen Component Index at 14316.64 points, down 0.85% [1][4][7] - Among the 30 sectors tracked, 9 sectors saw gains, with non-ferrous metals, oil, petrochemicals, and coal leading the increases, while defense, automotive, and comprehensive finance sectors faced significant declines [1][4][7] - The total trading volume of the A-share market reached 32,806 billion, showing a slight increase compared to the previous day [1][4][7] Overseas Market Overview - The three major U.S. stock indices all closed higher, with the Dow Jones up 0.64%, the S&P 500 up 0.5%, and the Nasdaq up 0.43%. Notably, Cisco rose over 3% and Apple nearly 3%, leading the Dow [2][4] - The Nasdaq Golden Dragon China Index fell by 0.6%, with Baidu dropping over 3% and Xpeng Motors down over 2% [2][4] Key News Highlights - The Ministry of Commerce announced plans to optimize the implementation of the old-for-new consumption policy [3][9] - By 2025, domestic residents are expected to travel 6.522 billion times, a year-on-year increase of 16.2% [11] - The Ministry of Foreign Affairs stated that the establishment of a new strategic partnership between China and Canada is beneficial for global peace and stability [12] Driving Factors - Recent policies aimed at fostering new growth points in service consumption are set to be introduced, including measures to expand inbound consumption and optimize the old-for-new consumption policy for durable goods like automobiles and home appliances [8] - On the same day, 1,604 stocks rose while 3,771 fell, indicating a market in consolidation with a focus on macroeconomic data [8]

Market Overview - The A-share market saw most indices decline today, with the Shanghai Composite Index slightly down by 0.09% closing at 4132.61 points, the Shenzhen Component Index down by 0.85% at 14316.64 points, the ChiNext Index down by 0.91% at 3319.15 points, and the STAR 50 Index down by 1.35% at 1532.8 points [1] - Overall, there were 1602 stocks that rose and 3767 stocks that fell, with a total trading volume of 32,482 billion yuan, an increase of 1630 billion yuan compared to the previous trading day [1] Industry Performance - Among the primary industries, non-ferrous metals, petroleum and petrochemicals, coal, agriculture, forestry, animal husbandry, and fishery led the gains with increases of 4.57%, 3.18%, 2.07%, 0.85%, and 0.79% respectively [1] - Conversely, industries such as defense and military, automotive, social services, electronics, and real estate experienced declines, with decreases of 4.47%, 2.31%, 2.30%, 2.24%, and 2.23% respectively [1] Concept Sector Performance - The top-performing concept sectors included gold and jewelry, vaccines, selected rare metals, animal health, blood products, industrial metals, nickel ore, rare earths, influenza, cobalt ore, small metals, and biotechnology [2] - Sectors such as satellite internet, commercial aerospace, satellite navigation, and military information technology experienced pullbacks [2]

Core Viewpoint - Watson Bio's stock has shown fluctuations in price and trading volume, with a notable increase in share price since the beginning of the year, despite recent declines in the short term [1]. Financial Performance - For the period from January to September 2025, Watson Bio reported a revenue of 1.719 billion yuan, representing a year-on-year decrease of 19.73% [2]. - The net profit attributable to shareholders for the same period was 163 million yuan, down 36.24% year-on-year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Watson Bio was 114,000, a decrease of 2.75% from the previous period [2]. - The average number of circulating shares per shareholder increased by 2.83% to 13,643 shares [2]. Dividend Distribution - Since its A-share listing, Watson Bio has distributed a total of 451 million yuan in dividends, with 95.96 million yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, the largest circulating shareholder was E Fund's ChiNext ETF, holding 34.4714 million shares, a decrease of 5.8005 million shares from the previous period [3]. - Other notable institutional shareholders include Southern CSI 500 ETF and China Merchants National Bio-Medical Index A, both of which also saw reductions in their holdings [3].

Core Viewpoint - The stock of Zhifei Biological experienced a decline, with a current price of 19.03 yuan per share and a market capitalization of 45.554 billion yuan, reflecting a challenging financial performance in recent periods [1]. Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 7.627 billion yuan, a significant year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -1.206 billion yuan, marking a year-on-year decline of 156.10% [2]. - The company has cumulatively distributed dividends of 7.318 billion yuan since its A-share listing, with 3.194 billion yuan distributed over the past three years [3]. Shareholder and Market Activity - As of December 19, 2025, the number of shareholders for Zhifei Biological was 124,500, a decrease of 2.69% from the previous period, while the average circulating shares per person increased by 2.76% to 11,358 shares [2]. - The stock experienced a net outflow of main funds amounting to 25.6679 million yuan, with significant selling pressure observed in large orders [1]. Company Overview - Zhifei Biological, established on July 20, 1995, and listed on September 28, 2010, is primarily engaged in the research, production, and sales of vaccines and biological products. Its revenue composition includes 88.84% from agency products, 10.15% from self-developed products, and 1.00% from other sources [1]. - The company operates within the pharmaceutical and biological industry, specifically in the vaccine sector, and is associated with concepts such as hepatitis treatment, vaccines, anti-influenza, biomedicine, and innovative drugs [1]. Institutional Holdings - As of September 30, 2025, major institutional shareholders included Hong Kong Central Clearing Limited, holding 33.5608 million shares, and several ETFs, all of which saw a reduction in their holdings compared to the previous period [3].

Group 1 - The stock price of Global Printing increased by 2.38% on January 14, reaching 9.91 CNY per share, with a total market capitalization of 3.172 billion CNY [1] - The company has seen a year-to-date stock price increase of 16.18%, with a 13.39% rise over the last five trading days and an 18.97% increase over the last 60 days [1] - Global Printing's main business involves the design, production, and sales of pharmaceutical packaging products, contributing 48.31% to its revenue, followed by printing supply chain business at 35.90% and internet digital marketing at 15.04% [1] Group 2 - As of September 30, the number of shareholders for Global Printing decreased by 1.37% to 23,800, while the average circulating shares per person increased by 1.39% to 13,435 shares [2] - For the period from January to September 2025, Global Printing reported a revenue of 619 million CNY, a decrease of 44.12% year-on-year, and a net profit attributable to shareholders of -20.06 million CNY, down 173.05% [2] - The company has distributed a total of 72.57 million CNY in dividends since its A-share listing, with 17.92 million CNY distributed over the last three years [3]

Core Viewpoint - The stock price of Pulaike has shown a positive trend with a year-to-date increase of 6.44%, reflecting a strong performance in the animal health sector [2] Group 1: Stock Performance - As of January 13, Pulaike's stock price rose by 2.00% to 13.23 CNY per share, with a trading volume of 46.33 million CNY and a turnover rate of 1.02% [1] - The stock has increased by 3.93% over the last five trading days and 2.40% over the last twenty days, while it has decreased by 4.68% over the last sixty days [2] Group 2: Company Overview - Pulaike Bioengineering Co., Ltd. was established on June 22, 2002, and went public on May 18, 2015. The company is primarily engaged in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [2] - The revenue composition of Pulaike includes poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [2] Group 3: Financial Performance - For the period from January to September 2025, Pulaike achieved an operating income of 823 million CNY, representing a year-on-year growth of 8.04%. The net profit attributable to shareholders was 157 million CNY, reflecting a significant increase of 47.86% [2] - Since its A-share listing, Pulaike has distributed a total of 1.125 billion CNY in dividends, with 568 million CNY distributed over the past three years [3] Group 4: Shareholder Information - As of September 30, 2025, Pulaike had 16,700 shareholders, a decrease of 7.26% from the previous period, with an average of 20,739 circulating shares per shareholder, an increase of 7.83% [2] - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF ranks as the sixth largest, holding 5.4716 million shares, an increase of 2.0217 million shares from the previous period [3]

Core Viewpoint - Changchun High-tech's stock price has shown a significant increase this year, with a notable rise in recent trading days, despite a decline over the past two months [1][2]. Group 1: Stock Performance - As of January 13, Changchun High-tech's stock price increased by 2.01%, reaching 105.65 CNY per share, with a trading volume of 7.11 billion CNY and a turnover rate of 1.72% [1]. - Year-to-date, the stock price has risen by 14.15%, with a 10.12% increase over the last five trading days and a 12.81% increase over the last 20 days, while it has decreased by 12.88% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Changchun High-tech reported a revenue of 9.807 billion CNY, a year-on-year decrease of 5.60%, and a net profit attributable to shareholders of 1.165 billion CNY, down 58.23% year-on-year [2]. - The company has distributed a total of 4.791 billion CNY in dividends since its A-share listing, with 3.259 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Changchun High-tech was 104,100, a decrease of 4.63% from the previous period, with an average of 3,840 circulating shares per shareholder, an increase of 4.85% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest, holding 9.7451 million shares, an increase of 1.307 million shares from the previous period [3].

Group 1 - The core viewpoint of the news is that Kanghua Biological has experienced fluctuations in stock price and financial performance, with a notable decrease in revenue and net profit year-on-year [1][2][3] Group 2 - As of January 9, Kanghua Biological's stock price increased by 2.03% to 75.50 CNY per share, with a total market capitalization of 9.811 billion CNY [1] - The company has seen a year-to-date stock price increase of 4.48%, but a decline of 4.50% over the past 20 days and 2.84% over the past 60 days [1] - Kanghua Biological's main business involves comprehensive research, development, and operation of vaccines, with 99.99% of its revenue coming from non-immunization planning vaccines [1] Group 3 - As of September 30, the number of shareholders for Kanghua Biological increased by 6.13% to 18,300, while the average number of circulating shares per person decreased by 8.10% to 6,502 shares [2] - For the period from January to September 2025, Kanghua Biological reported a revenue of 840 million CNY, a year-on-year decrease of 20.78%, and a net profit attributable to shareholders of 189 million CNY, down 53.41% year-on-year [2] Group 4 - Since its A-share listing, Kanghua Biological has distributed a total of 686 million CNY in dividends, with 462 million CNY distributed over the past three years [3] - As of September 30, 2025, the fifth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 1.1826 million shares as a new shareholder [3] - The seventh largest circulating shareholder is Southern CSI 1000 ETF, holding 850,600 shares, which is a decrease of 11,100 shares compared to the previous period [3]